In the BioHarmony Drug Report Database

"Preview" Icon

Risperidone

Perseris, Risperdal, Risperdal Consta (risperidone) is a small molecule pharmaceutical. Risperidone was first approved as Perseris on 1993-12-29. It is used to treat autistic disorder, bipolar disorder, dementia, schizophrenia, and schizophrenia spectrum and other psychotic disorders amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. In addition, it is known to target D(3) dopamine receptor, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1E, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2C, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 1F, and e Lysozyme murein hydrolase. Risperdal’s patents are valid until 2028-02-13 (FDA).

 

Trade Name

 

Perseris, Risperdal, Risperdal Consta
 

Common Name

 

risperidone
 

ChEMBL ID

 

CHEMBL85
 

Indication

 

autistic disorder, bipolar disorder, dementia, schizophrenia, schizophrenia spectrum and other psychotic disorders, tourette syndrome
 

Drug Class

 

Antipsychotics (risperidone type)

Image (chem structure or protein)

Risperidone structure rendering